We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 1-20 of 319 results
  1. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study

    Introduction

    Long-acting lipoglycopeptides such as dalbavancin may have utility in patients with Gram-positive bloodstream infections (BSI),...

    Nicholas Rebold, Sara Alosaimy, ... Michael J. Rybak in Infectious Diseases and Therapy
    Article Open access 01 March 2024
  2. Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection

    Background

    Dalbavancin is a lipoglycopeptide antibiotic approved for treatment of skin and soft tissue infections, administered as a single or...

    Anna Lange, Ulrica Thunberg, Bo Söderquist in BMC Infectious Diseases
    Article Open access 19 October 2023
  3. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service

    Purpose

    Dalbavancin, approved in 2014 for Gram-positive acute bacterial skin and skin structure infections (ABSSSI), has pharmacokinetics enabling...

    James C McSorley, Darshini Reyes, ... Vhairi Bateman in Infection
    Article Open access 02 January 2024
  4. In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry

    Purpose

    Although dalbavancin is currently approved for the treatment of ABSSIs, several studies suggest its efficacy and tolerance as long-term...

    Silvano Esposito, Pasquale Pagliano, ... Enrico Trecarichi in Infection
    Article Open access 07 February 2024
  5. Effective use of a two-dose regimen of dalbavancin to treat prosthetic joint infections and spinal hardware infections

    Purpose

    Dalbavancin is an attractive antibiotic for the treatment of Gram-positive musculoskeletal infections given its long half-life and prolonged...

    James B. Doub, Talal Alkayali, ... Rohit Talwani in European Journal of Orthopaedic Surgery & Traumatology
    Article 04 June 2023
  6. Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin

    Introduction

    Daptomycin (DAP) has proven to be a viable alternative amid vancomycin resistance; however, the use of DAP post vancomycin treatment has...

    Razieh Kebriaei, Jacinda C. Abdul-Mutakabbir, ... Michael J. Rybak in Infectious Diseases and Therapy
    Article Open access 05 October 2023
  7. Dalbavancin

    Article 24 February 2024
  8. Dalbavancin

    Article 25 May 2024
  9. Dalbavancin

    Article 09 March 2024
  10. Dalbavancin

    Article 25 May 2024
  11. Dalbavancin

    Article 08 June 2024
  12. Dalbavancin

    Article 07 January 2023
  13. Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin

    Dalbavancin is a synthetic lipoglycopeptide that exerts its antimicrobial activity through two distinct modes of action, inhibition of cell wall...

    Kyle C. Molina, Matthew A. Miller, ... Tyree H. Kiser in Clinical Pharmacokinetics
    Article 21 December 2021
  14. Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals

    Introduction

    The extended half-life of dalbavancin justifies a once-a-week dosing schedule and is supposed to favour early discharge. These advantages...

    Guillaume Béraud, Jean-Claude Maupetit, ... Martin Blachier in Infectious Diseases and Therapy
    Article Open access 15 December 2021
  15. Dalbavancin

    Article 24 September 2022
  16. A Dalbavancin Lock Solution Can Reduce Enterococcal Biofilms After Freezing

    Introduction

    We previously demonstrated the efficacy of a frozen dalbavancin–heparin (DH) lock solution against biofilms of staphylococci. However, as...

    Marta Díaz-Navarro, Rama Hafian, ... María Guembe in Infectious Diseases and Therapy
    Article Open access 16 January 2022
Did you find what you were looking for? Share feedback.